163 related articles for article (PubMed ID: 35259444)
1. Screening bioactive compounds from Danggui-shaoyao-san for treating sodium retention in nephrotic syndrome using bio-affinity ultrafiltration.
Yang M; Ni L; Wang Y; Xuan Z; Wu H; Zhan W; Wan X; Wang J; Xu F
J Ethnopharmacol; 2022 Jun; 292():115171. PubMed ID: 35259444
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the mechanism of Danggui-Shaoyao-San in regulating the metabolome of nephrotic syndrome based on urinary metabonomics and bioinformatics approaches.
Wang Y; Fan S; Yang M; Shi G; Hu S; Yin D; Zhang Y; Xu F
J Ethnopharmacol; 2020 Oct; 261():113020. PubMed ID: 32592886
[TBL] [Abstract][Full Text] [Related]
3. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
5. Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking.
Li L; Kong J; Yao CH; Liu XF; Liu JH
J Pharm Biomed Anal; 2019 Feb; 164():241-248. PubMed ID: 30396051
[TBL] [Abstract][Full Text] [Related]
6. Integrated UPLC-Q-TOF-MS and network pharmacology approach-driven quality marker discovery of Danggui Shaoyao San for primary dysmenorrhea.
Li Z; Xiong H; Li N; Zhao L; Liu Z; Yu Y; Zhao C
Biomed Chromatogr; 2023 May; 37(5):e5608. PubMed ID: 36805594
[TBL] [Abstract][Full Text] [Related]
7. Acute toxicology on Danio rerio embryo and adult from Chinese traditional medicine preparation Danggui Shaoyao san.
Luo R; He C; He J; Li Z; Wang Y; Hou M; Li P; Yu W; Cheng S; Song Z
J Ethnopharmacol; 2024 Mar; 321():117528. PubMed ID: 38043754
[TBL] [Abstract][Full Text] [Related]
8. Systems pharmacological study based on UHPLC-Q-Orbitrap-HRMS, network pharmacology and experimental validation to explore the potential mechanisms of Danggui-Shaoyao-San against atherosclerosis.
Bi Y; Han X; Lai Y; Fu Y; Li K; Zhang W; Wang Q; Jiang X; Zhou Y; Liang H; Fan H
J Ethnopharmacol; 2021 Oct; 278():114278. PubMed ID: 34087397
[TBL] [Abstract][Full Text] [Related]
9. High-throughput UPLC-Q-TOF-MS/MS coupled with multivariable data processing approach for the rapid screening and characterization of chemical constituents and potential bioactive compounds from Danggui Shaoyao San.
Li N; Yu Y; Cui X; Liu Q; Xiong H
Biomed Chromatogr; 2022 Sep; 36(9):e5420. PubMed ID: 35638160
[TBL] [Abstract][Full Text] [Related]
10. Potential hemostatic compounds targeting urokinase plasminogen activator explored from three Euphorbiaceae species: Euphorbia maculata, Euphorbia humifusa, and Acalypha australis, with bio-affinity ultrafiltration UPLC-MS.
Rakotondrabe TF; Fan M; Hu G; Guo M
Phytochem Anal; 2024 Jan; 35(1):28-39. PubMed ID: 37571866
[TBL] [Abstract][Full Text] [Related]
11. Extract of Danggui-Shaoyao-San ameliorates cognition deficits by regulating DHA metabolism in APP/PS1 mice.
Huang J; Wang X; Xie L; Wu M; Zhao W; Zhang Y; Wang Q; Yao L; Li W
J Ethnopharmacol; 2020 May; 253():112673. PubMed ID: 32084555
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2019 Dec; 227(4):e13362. PubMed ID: 31423748
[TBL] [Abstract][Full Text] [Related]
13. Danggui-Shaoyao San alleviates cognitive impairment via enhancing HIF-1α/EPO axis in vascular dementia rats.
Ningning Y; Ying X; Xiang L; Yue S; Zhongda W; Ruoyu J; Hanwen S; Weiwei T; Yafeng Z; Junjie M; Xiaolan C
J Ethnopharmacol; 2024 Sep; 331():118306. PubMed ID: 38723920
[TBL] [Abstract][Full Text] [Related]
14. Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
Chen JL; Wang L; Yao XM; Zang YJ; Wang Y; Li ZJ; Pearce D; Wang H
Am J Nephrol; 2019; 50(2):92-104. PubMed ID: 31269481
[TBL] [Abstract][Full Text] [Related]
15. Sodium retention by uPA-plasmin-ENaC in nephrotic syndrome-Authors reply.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2020 Apr; 228(4):e13432. PubMed ID: 31845496
[No Abstract] [Full Text] [Related]
16. Screening and characterization of aldose reductase inhibitors from Traditional Chinese medicine based on ultrafiltration-liquid chromatography mass spectrometry and in silico molecular docking.
Zhang H; Xu C; Tian Q; Zhang Y; Zhang G; Guan Y; Tong S; Yan J
J Ethnopharmacol; 2021 Jan; 264():113282. PubMed ID: 32890716
[TBL] [Abstract][Full Text] [Related]
17. Proteinuric diseases with sodium retention: Is plasmin the link?
Svenningsen P; Skøtt O; Jensen BL
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):117-24. PubMed ID: 21466573
[TBL] [Abstract][Full Text] [Related]
18. A systems pharmacology approach to decipher the mechanism of danggui-shaoyao-san decoction for the treatment of neurodegenerative diseases.
Luo Y; Wang Q; Zhang Y
J Ethnopharmacol; 2016 Feb; 178():66-81. PubMed ID: 26680587
[TBL] [Abstract][Full Text] [Related]
19. Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats.
Yin J; Lu J; Lei P; He M; Huang S; Lv J; Zhu Y; Liu Z; Jiang M
Front Pharmacol; 2021; 12():671708. PubMed ID: 34326769
[TBL] [Abstract][Full Text] [Related]
20. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.
Andersen RF; Buhl KB; Jensen BL; Svenningsen P; Friis UG; Jespersen B; Rittig S
Pediatr Nephrol; 2013 Aug; 28(8):1227-34. PubMed ID: 23503750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
